Health Equity in Clinical Trials | Kisaco Research

Health Equity in Clinical Trials

Improving representation in design, recruitment, and retention.

Who we are:

We are a platform for sharing solutions to the biggest barriers facing health equity in drug development. Join our whole-ecosystem audience of pharmaceutical giants, biotechs, medtech, start-ups, CROs, sites, advocacy groups, patients, and academic excellence.

VIEW OUR EVENTS     CONTACT US

Who You Will Meet

Bringing together senior executives from large pharmaceutical and medical device companies, biotechs, startups, investors, CROs, patient advocacy groups, consultants, government representatives, regulatory experts, payers, non-profits, academic leaders and other supporting stakeholders, Health Equity in Clinical Trials Congress is dedicated to progressing industry alignment through collaboration and partnership whilst amplifying your DEI strategy.

40%
Pharmaceutical Companies, Biotechs, Medical Devices
20%
Academics, Non-profits, Advocacy Groups
20%
CROs, Service Providers
15%
Site Networks, Medical Institutions, Hospitals
5%
Government Representatives, Payers, Investors

Critical Needs Identified:

Health Equity in Clinical Trials is being accelerated through the FDA’s requirement of Diversity Action Plans. We take pharmaceutical companies on a journey from upstream preclinical studies, data science and goal setting to, DEI strategy deployment, to post-study marketing. No matter what function you sit in your next collaborator sits in our network whether you are coordinating a study, reviewing protocols, on the lookout for new vendors, or here to learn.

Our Congress is Designed for leadership in the following pharmaceutical functions:

  • DEI in Clinical Trials
  • Clinical Operations
  • Patient Engagement
  • Patient Advocacy
  • Regulatory Affairs
  • Medical Affairs
  • Medical Writing
  • Data Science, RWE
  • Epidemiology
  • Corporate Affairs
  • Marketing & Commercial
May, 2025

Contact us to learn more about our Series: